![OCHD COVID-19 CLINICS PROVIDING ADDITIONAL DOSE FOR MODERATELY OR SEVERELY IMMUNOCOMPROMISED INDIVIDUALS – Ocean County Health Department OCHD COVID-19 CLINICS PROVIDING ADDITIONAL DOSE FOR MODERATELY OR SEVERELY IMMUNOCOMPROMISED INDIVIDUALS – Ocean County Health Department](https://www.ochd.org/wp-content/uploads/2021/08/vaccine-5926664_1920-1.jpg)
OCHD COVID-19 CLINICS PROVIDING ADDITIONAL DOSE FOR MODERATELY OR SEVERELY IMMUNOCOMPROMISED INDIVIDUALS – Ocean County Health Department
![Second dose of AstraZeneca COVID-19 vaccine: FAQs about blood clots, safety, risks and symptoms | The Royal Society of Canada Second dose of AstraZeneca COVID-19 vaccine: FAQs about blood clots, safety, risks and symptoms | The Royal Society of Canada](https://rsc-src.ca/sites/default/files/file-20210527-21-1ne4g5u%20%281%29.jpeg)
Second dose of AstraZeneca COVID-19 vaccine: FAQs about blood clots, safety, risks and symptoms | The Royal Society of Canada
![COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7011e2_COVID19VaccineDose2_IMAGE_12Mar21_v4_1200x627.jpg?_=39294)
COVID-19 Vaccine Second-Dose Completion and Interval Between First and Second Doses Among Vaccinated Persons — United States, December 14, 2020−February 14, 2021 | MMWR
![Expiry date and shelf life of the AstraZeneca Covishield vaccine produced by the Serum Institute of India | WHO | Regional Office for Africa Expiry date and shelf life of the AstraZeneca Covishield vaccine produced by the Serum Institute of India | WHO | Regional Office for Africa](https://www.afro.who.int/sites/default/files/2021-05/WHO_20210304_GHANA_COVAX%20STORIES_073.jpg)